Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs

Shares of Moderna Inc. traded up double-digits today as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus. This morning clinical-stage biotechnology company Mode...
Streetwise Reports | September 13, 2019 |

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%

Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. Earlier today clinical-stage biopharmaceutical firm Global Blood Therapeuti...
Streetwise Reports | September 6, 2019 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

Q2 Earnings Soar for AI-Assisted Advertising Technology Firm

This small-cap firm saw rapid growth and reported a record second quarter. Adcore Inc. (ADCO:TSX.V) , the developer of machine-learning powered advertising technologies, reported record second quarter financials, including an increase in revenue growth of 53% year o...
Streetwise Reports | August 30, 2019 |

GameSquare: Own the future of sport

The following is a transcription of the above video, and The Market Online has edited it for clarity . Our next company is GameSquare Holdings Inc. (TSXV:GAME) , a vertically integrated, international digital media entertainment and technology company. We rece...
Ryan Dhillon | March 21, 2024 |

Western Refining (WNR): Pessimism has primed the pump for a rally

Independent crude oil refiner Western Refining Inc. ( NYSE: WNR ) is slated to step into the earnings limelight ahead of the open on Thursday, Nov. 4. Currently, Wall Street is looking for a profit of 12 cents per share from the company, a vast improvement over WNR's loss ...
Joseph Hargett | October 28, 2012 |

Tax-Loss Selling Drives Down Junior Stock Prices

Vista Gold Corp. (VGZ:NYSE.MKT; VGZ:TSX, US$0.59) has published an updated prefeasibility study (PFS) on its Mt Todd project in the Northern Territories in Australia, the largest undeveloped gold project in that country. The revisions to the old PFS include updating bo...
Streetwise Reports | November 28, 2019 |

Junior Exploration Companies on Adrian Day's Buy List

Evrim Resources Corp. (EVM:TSX.V, Toronto, 0.315) is coming closer to generating long-term revenue. The Ermitano project it discovered and sold to First Majestic keeping a royalty is on track for a Q1 2021 production start-up. The property is adjacent to First Majestic's...
Streetwise Reports | January 30, 2020 |

Fiscal Year 'Reads Well' for Regenerative Medicine Company

The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report. In an Aug. 30 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported Mesoblast Ltd.'s (MESO:NASDAQ; MSB:ASX) financial results for Q4/19 and fiscal year 2019 (FY19)...
Streetwise Reports | September 5, 2019 |

NCI Chooses Veterinary Biopharma as Select Manufacturing Contractor

The contract's meaning, terms and benefits and the California firm's near-term catalysts are discussed in an H.C. Wainwright & Co. report. In a Sept. 12 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Kindred Biosciences Inc. (KIN:NA...
Streetwise Reports | September 19, 2019 |
1 2 3 4 5 6 7 8 9 10 ...